Apr 05, 2012, 10.58 PM | Source: CNBC-TV18
Bio-pharma major Biocon on expansion mode.
Biocon is banking on a strong research pipeline. The company's focus on oral insulin will continue.
Kiran Mazumdar-Shaw, chairman and managing director, Biocon
says, the big change in our strategy would be that from having one global partner which was Pfizer, we'll have multiple partners.
Vijay Chopra of enochventures.com advises buying C
The biosimilar product, which is developed and man
The company plans to invest USD 100 million (aroun
Of USD 200 million capex, USD 100 million will go